Suchergebnisse - "145155-23-3"

PubPharm (101)

1

Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir : A Phase 2 Open-label Randomized Controlled Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Tam, A. | Zhang, R. | Lung, K. | +23

2

Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study

enthalten in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | 2022

von Korobko, D. | Barabanova, M. | Bakhtiyarova, K. | +4

3

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19 : a randomised clinical trial

enthalten in: Annals of medicine | 2021

von Li, C. | Luo, F. | Liu, C. | +24

4

Interferon β-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease

enthalten in: Journal of medical virology | 2021

von Tortajada, C. | Añón, S. | Ortiz, M. | +2

5

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome

enthalten in: The New England journal of medicine | 2020

von Arabi, Y. | Asiri, A. | Assiri, A. | +49

6

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial

enthalten in: Lancet (London, England) | 2020

von Hung, I. | Lung, K. | Tso, E. | +41

CommentIn: Lancet. 2020 May 30;395(10238):1670-1671. - PMID 32401712

7

Vitamin D, smoking, EBV, and long-term cognitive performance in MS : 11-year follow-up of BENEFIT

enthalten in: Neurology | 2020

von Cortese, M. | Munger, K. | Martínez-Lapiscina, E. | +115

CommentIn: Neurology. 2020 May 5;94(18):771-772. - PMID 32300061

8

Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis

enthalten in: Journal of neuroimmunology | 2019

von Abdel-Dayem, M. | Shaker, M. | Gameil, N.

9

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2019

von Buck, D. | Andlauer, T. | Igl, W. | +19

10

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis : an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

enthalten in: Journal of neurology | 2017

von Comi, G. | Patti, F. | Rocca, M. | +42

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]